Mark Bonyhadi obtained his Ph.D. in immunology from UC Berkeley, where he studied T cell developmental biology, with an emphasis on molecular immunology and T cell differentiation. Dr. Bonyhadi did his post-doctoral training at SyStemix, in Palo Alto studying the mechanism of HIV pathogenesis in the SCID-hu mouse model. He worked at SyStemix as a senior scientist developing organ culture models for screening antiviral candidate compounds, as well as further defining mechanisms of HIV pathogenesis. He was group leader for T cell studies related to hematopoietic stem cell-based gene therapy for HIV, using both moloney and lenti-base vector systems. His group conducted the animal studies for safety, function and efficacy for gene-modified stem cells as part of the successful IND for evaluating the therapy in human trials. In 1997, he joined Xcyte Therapies in Seattle as VP of Research, where he directed the preclinical development of Xcyte’s proprietary T cell activation and expansion technology, which led to a successful IND submission and ensuing human clinical studies. He was also responsible for scientific liaisons and outside collaborations related to gene therapy, HIV infection, autoimmunity, and oncology. In 2006, Dr. Bonyhadi joined Invitrogen, now Life Technologies, where he has been responsible for identifying and implementing Invitrogen business opportunities aligned with their cell therapy portfolio, participating in the development of new products optimized for cell therapy applications, as well as working with academia and industry to accelerate the development of novel cell-based therapeutics.
Biography Updated on 29 December 2011